Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
Original Article
M. Greenhawt, S.B. Sindher, J. Wang, M. O’Sullivan, G.d. Toit, E.H. Kim, D. Albright, S. Anvari, N. Arends, P.D. Arkwright, P. Bégin, K. Blumchen, T. Bourrier, T. Brown-Whitehorn, H. Cassell, E.S. Chan, C.E. Ciaccio, A. Deschildre, A. Divaret-Chauveau, S.L. Dorris, M.J. Dorsey, T. Eiwegger, M. Erlewyn-Lajeunesse, D.M. Fleischer, L.S. Ford, M. Garcia-Lloret, L. Giovannini-Chami, J.O. Hourihane, N. Jay, S.M. Jones, L.A. Kerns, K.M. Kloepfer, S. Leonard, G. Lezmi, J.A. Lieberman, J. Lomas, M. Makhija, C. Parrish, J. Peake, K.P. Perrett, D. Petroni, W. Pfützner, J.A. Pongracic, P. Quinn, R.G. Robison, G. Sanders, L. Schneider, H.P. Sharma, J. Trujillo, P.J. Turner, K. Tuttle, J.E. Upton, P. Varshney, B.P. Vickery, C. Vogelberg, B. Wainstein, R.A. Wood, K.J. Bee, D.E. Campbell, T.D. Green, R. Rouissi, A. Peillon, H.T. Bahnson, T. Bois, H.A. Sampson, and A.W. Burks
N Engl J Med 2023;388:1755-1766
Course summary
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation

Facebook
X
LinkedIn
Forward